Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
14.62
+0.11 (0.76%)
Nov 20, 2024, 4:00 PM EST - Market closed
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $48.00M in the quarter ending September 30, 2024, with 50.00% growth. This brings the company's revenue in the last twelve months to $263.00M, up 119.17% year-over-year. In the year 2023, Arcus Biosciences had annual revenue of $117.00M with 4.46% growth.
Revenue (ttm)
$263.00M
Revenue Growth
+119.17%
P/S Ratio
4.78
Revenue / Employee
$455,806
Employees
577
Market Cap
1.35B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.26B |
Indivior | 1.18B |
Novavax | 885.19M |
Alphatec Holdings | 572.74M |
STAAR Surgical Company | 341.22M |
Syndax Pharmaceuticals | 16.00M |
ARS Pharmaceuticals | 2.57M |
Praxis Precision Medicines | 1.61M |
RCUS News
- 1 day ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 8 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 14 days ago - Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update - Business Wire
- 16 days ago - Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer - Business Wire
- 22 days ago - Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting - Business Wire
- 4 weeks ago - First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer - Business Wire
- 4 weeks ago - Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update - Business Wire